Nectar Lifesciences Limited
Nectar Lifesciences Limited (NECLIFE) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
neclife.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 398 Cr | 452 Cr | 441 Cr | 359 Cr | 428 Cr | 455 Cr | 431 Cr | 281 Cr | 5 Cr | 0 Cr | 0 Cr | 0.01 Cr |
| Operating expenses (approx.) | 371 Cr | 410 Cr | 393 Cr | 319 Cr | 385 Cr | 410 Cr | 585 Cr | 343 Cr | 6 Cr | 2 Cr | 59 Cr | 28 Cr |
| EBITDA | 27 Cr | 42 Cr | 49 Cr | 40 Cr | 43 Cr | 45 Cr | -154 Cr | -62 Cr | -1 Cr | -2 Cr | -59 Cr | -28 Cr |
| OPM % | 6.8% | 9.3% | 11.0% | 11.1% | 10.1% | 9.8% | -35.8% | -22.1% | -20.9% | — | — | -191031.0% |
| Other income | 11 Cr | 0.48 Cr | 1 Cr | 0.55 Cr | 0.69 Cr | 0.57 Cr | 0.08 Cr | 0.35 Cr | 0.74 Cr | 0.66 Cr | 8 Cr | 3 Cr |
| Interest | 21 Cr | 25 Cr | 24 Cr | 20 Cr | 20 Cr | 17 Cr | 18 Cr | 19 Cr | 0 Cr | 30 Cr | 6 Cr | 0.16 Cr |
| Depreciation | 15 Cr | 15 Cr | 15 Cr | 15 Cr | 16 Cr | 16 Cr | 16 Cr | 17 Cr | 0.20 Cr | 0.06 Cr | 0.08 Cr | 0.11 Cr |
| Profit before tax | 2 Cr | 2 Cr | 11 Cr | 5 Cr | 9 Cr | 13 Cr | -188 Cr | -97 Cr | -271 Cr | -40 Cr | -130 Cr | -24 Cr |
| Tax % | 38.1% | 36.2% | 94.7% | 39.6% | 35.4% | 37.5% | 30.7% | 34.6% | 0.1% | 27.6% | 15.2% | 36.9% |
| Net profit | 1 Cr | 2 Cr | 0.59 Cr | 3 Cr | 6 Cr | 8 Cr | -130 Cr | -63 Cr | -176 Cr | 14 Cr | -68 Cr | -15 Cr |
| EPS (₹) | ₹0.05 | ₹0.07 | ₹0.03 | ₹0.13 | ₹0.25 | ₹0.35 | ₹-5.80 | ₹-2.82 | ₹-7.84 | ₹0.64 | ₹-3.38 | ₹-0.79 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,783 Cr | 2,367 Cr | 1,544 Cr | 1,669 Cr | 1,525 Cr | 1,686 Cr | 1,673 Cr | 0 Cr | Sign in for TTM |
| Operating expenses (approx.) | 2,519 Cr | 2,147 Cr | 1,434 Cr | 1,510 Cr | 1,471 Cr | 1,533 Cr | 1,700 Cr | 61 Cr | Sign in for TTM |
| EBITDA | 264 Cr | 220 Cr | 110 Cr | 159 Cr | 54 Cr | 153 Cr | -26 Cr | -61 Cr | Sign in for TTM |
| OPM % | 9.5% | 9.3% | 7.1% | 9.5% | 3.5% | 9.1% | -1.6% | — | Sign in for TTM |
| Other income | 6 Cr | 4 Cr | 3 Cr | 11 Cr | 42 Cr | 13 Cr | 2 Cr | 9 Cr | Sign in for TTM |
| Interest | 148 Cr | 126 Cr | 112 Cr | 79 Cr | 79 Cr | 87 Cr | 75 Cr | 36 Cr | Sign in for TTM |
| Depreciation | 63 Cr | 61 Cr | 60 Cr | 57 Cr | 59 Cr | 61 Cr | 62 Cr | 0.34 Cr | Sign in for TTM |
| Profit before tax | 59 Cr | 37 Cr | -85 Cr | 34 Cr | -42 Cr | 18 Cr | -162 Cr | -462 Cr | Sign in for TTM |
| Tax % | 19.1% | 15.2% | 13.6% | 26.5% | 43.0% | 72.7% | 29.6% | 6.6% | Sign in for TTM |
| Net profit | 48 Cr | 32 Cr | -73 Cr | 25 Cr | -24 Cr | 5 Cr | -114 Cr | -293 Cr | Sign in for TTM |
| EPS (₹) | ₹2.12 | ₹1.42 | ₹-3.27 | ₹1.12 | ₹-1.08 | ₹0.22 | ₹-5.07 | ₹-13.40 | Sign in for TTM |
| Dividend payout % | — | — | — | 0.0% | — | 0.0% | — | — | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 22 Cr | 22 Cr | 22 Cr | 22 Cr | 22 Cr | 22 Cr | 22 Cr | 19 Cr |
| Reserves | 1,083 Cr | 1,114 Cr | 1,040 Cr | 1,065 Cr | 1,042 Cr | 1,047 Cr | 934 Cr | 563 Cr |
| Borrowings | — | — | — | — | 754 Cr | 636 Cr | 582 Cr | — |
| Other liabilities | — | — | — | — | 371 Cr | 486 Cr | 509 Cr | 39 Cr |
| Total liabilities | — | — | — | — | 2,189 Cr | 2,191 Cr | 2,047 Cr | 622 Cr |
| Fixed assets (net) | — | — | — | — | 613 Cr | 590 Cr | 577 Cr | 103 Cr |
| CWIP | — | — | — | — | 78 Cr | 66 Cr | 57 Cr | 0 Cr |
| Investments | — | — | — | — | 0.55 Cr | 0.73 Cr | 0.76 Cr | 13 Cr |
| Loans & advances | — | — | — | — | 0.37 Cr | 0.92 Cr | 0.86 Cr | 0.09 Cr |
| Inventories | — | — | — | — | 673 Cr | 709 Cr | 690 Cr | 0.30 Cr |
| Trade receivables | — | — | — | — | 280 Cr | 379 Cr | 345 Cr | 0 Cr |
| Cash & bank | — | — | — | — | 18 Cr | 20 Cr | 19 Cr | 0 Cr |
| Other assets | — | — | — | — | 528 Cr | 425 Cr | 357 Cr | 505 Cr |
| Total assets | — | — | — | — | 2,189 Cr | 2,191 Cr | 2,047 Cr | 622 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 95 Cr | 134 Cr | 225 Cr | 169 Cr | -349 Cr |
| Cash from investing | — | — | — | 17 Cr | 52 Cr | -17 Cr | -42 Cr | 1,208 Cr |
| Cash from financing | — | — | — | -119 Cr | -186 Cr | -205 Cr | -128 Cr | -767 Cr |
| Net cash flow | — | — | — | -8 Cr | -0.23 Cr | 2 Cr | -0.58 Cr | 93 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 70 Cr | 104 Cr | 195 Cr | 126 Cr | -361 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 18.7% | 14.4% | 2.6% | 10.4% | 2.0% | 6.2% | -5.7% | -73.2% |
| ROE % | 4.3% | 2.8% | -6.9% | 0.0% | 0.0% | 0.0% | -11.9% | -50.3% |
| Debtor days | — | — | — | — | 67 | 82 | 75 | — |
| Inventory days | — | — | — | — | 204 | 208 | 201 | — |
| Days payable | — | — | — | — | 97 | 123 | 128 | — |
| Cash conversion cycle | — | — | — | — | 174 | 167 | 149 | — |
| Debt / equity | — | — | — | — | 0.71 | 0.59 | 0.61 | — |
| Current ratio | — | — | — | — | 1.38 | 1.32 | 1.21 | 9.71 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 13.65 | 4.02 | — | — |
Compare with peers
Loading peers…